

## Futura Medical

### MED3000 European regulatory pathway is clearer

17 February 2020

- Futura Medical has announced that it has had positive discussions with the European regulators regarding the approval of MED3000 as a medical device for the treatment of erectile dysfunction (ED). MED3000 is the project name for the base MED2005 DermaSys formulation used as the placebo in the pivotal FM57 Phase III study.
- The discussions clarified the regulatory requirements and it appears that the full FM57 data, together with the usual technical dossiers, will be sufficient for European approval. Management expects the technical files will be ready for submission by mid-2020.
- The FM57 Phase III trial for MED2005, an erectogenic gel containing glyceryl trinitrate (GTN), showed MED2005 met the primary endpoints against baseline and, rather surprisingly, also demonstrated a significant clinical benefit for the DermaSys gel formulation alone (now MED3000).
- MED3000 appears to work through a specific and targeted evaporative effect which stimulates the nerve endings in the glans penis, causing an erection.
- The recent equity raise, along with existing cash resources, means that we believe sufficient funding is in place for the closing out costs for the FM57 study and to pursue a medical devices pathway for the regulatory approvals of MED3000. This assumes that MED3000 approval in the US would not require material additional clinical studies to be performed.
- The regulatory pathway in the US is expected to be similar, but cannot be confirmed until the face-to-face meeting with the FDA in Q120 has happened.
- The full data from FM57 is still being evaluated and will be presented once the analysis is complete. Completion of the clinical study report is expected by the end of April 2020.

Price	12.2p
Market Cap	£29.9m
Primary exchange	AIM
Sector	Healthcare
Company Code	FUM
Corporate client	Yes

#### Company description:

Futura Medical is an R&D driven small pharma company, with a novel DermaSys transdermal delivery platform. The lead programme, MED3000, is a topically applied gel being developed for erectile dysfunction (ED). A pain relief gel, TPR100, is awaiting UK approval.

**Trinity Delta view:** The remarkable FM57 pivotal study results have created understandable uncertainty. However, there are material commercial opportunities for MED3000 to be approved as a treatment for ED, including the extended patent life and wider market opportunities, eg use with existing ED medications such as PDE5 inhibitors. Clearly there are significant potential unknowns that remain. The positive interactions with the European regulators bring a welcome improved clarity to the likely approval pathway. The planned meeting with the FDA this quarter will shed further light on the next steps for the important US market. We suspended our forecasts and valuation at the time of the FM57 results and intend to reinstate them as soon as practicable.

#### Analysts

**Lala Gregorek**  
[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)  
 +44 (0) 20 3637 5043

**Franco Gregori**  
[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)  
 +44 (0) 20 3637 5041

**Mick Cooper**

[mcooper@trinitydelta.org](mailto:mcooper@trinitydelta.org)  
+44 (0) 20 3637 5042

**Lala Gregorek**

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)  
+44 (0) 20 3637 5043

**Franco Gregori**

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)  
+44 (0) 20 3637 5041

### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org). TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2020 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: [www.trinitydelta.org](http://www.trinitydelta.org)